Stockscreener 앱 받기
220.42
4.88%
10.26
시장 영업 전:
221.01
0.59
+0.27%
전일 마감가:
$210.16
열려 있는:
$209.41
하루 거래량:
1.43M
Relative Volume:
2.70
시가총액:
$13.47B
수익:
$534.57M
순이익/손실:
$-293.67M
주가수익비율:
-44.37
EPS:
-4.968
순현금흐름:
$-187.10M
1주 성능:
+7.29%
1개월 성능:
+10.64%
6개월 성능:
+28.96%
1년 성능:
+68.72%
1일 변동 폭
$207.52
$229.94
1주일 범위
$192.28
$229.94
52주 변동 폭
$118.03
$229.94
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
220.42 | 12.84B | 534.57M | -293.67M | -187.10M | -4.968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - setenews.com
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Sahm
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - setenews.com
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Is the Market Bullish or Bearish on Ascendis Pharma AS? - Sahm
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewswire Inc.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - Sahm
Ascendis Pharma ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - MSN
ASND | Ascendis Pharma A/S ADR SEC Filings - MarketWatch
European ADRs Slip As Gains And Losses Balance Out - Finimize
Take off with Ascendis Pharma A/S ADR (ASND): Get ready for trading - Setenews
How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone - Sahm
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Sahm
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - TradingView
Apple Upgraded, DraftKings Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 81 RS Rating - MSN
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism - Sahm
Should Positive Three-Year TransCon PTH Data Prompt Action From Ascendis Pharma (ASND) Investors? - Sahm
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Sahm
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Sahm
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Sahm
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation as Analyst Confidence Rises on Key EMA Filing - Sahm
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
How Ascendis Pharma’s (ASND) TransCon CNP EMA Submission Has Shaped Its Rare Disease Investment Story - Sahm
Should Investors Consider Ascendis Pharma After FDA Nod for Next-Gen Hormone Therapy in 2025? - Sahm
Raymond James initiates Ascendis Pharma stock with Strong Buy rating - Investing.com
Ascendis Pharma A/S Sponsored ADR (ASND) Stock Price Today | Live Chart & News - Traders Union
Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64 - Defense World
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Book value per share of Ascendis Pharma A/S Sponsored ADR – MUN:A71 - TradingView
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia - Sahm
Does Analyst Backing of Yorvipath Shift the Competitive Narrative for Ascendis Pharma (ASND)? - Sahm
Ascendis Pharma increases share capital following warrant exercises - Investing.com
Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts - Investing.com
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth - The Globe and Mail
Stocks To Watch: Sociedad Quimica ADR Sees Relative Strength Rating Rise To 80 - inkl
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 92 - Investor's Business Daily
Ascendis Pharma AS earnings beat by €0.45, revenue topped estimates - Investing.com
Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results - Investing.com
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 81 RS Rating - Investor's Business Daily
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Ascendis Pharma stock jumps after FDA approves SKYTROFA for adult GHD - Investing.com
Stocks Showing Rising Market Leadership: Gpo Aeroportuario ADR Earns 83 RS Rating - inkl
Ascendis Pharma reports positive results from hypothyroid trial - MSN
Ascendis Pharma stock rating assumed at Overweight by Morgan Stanley - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
Ascendis Pharma A S Adr (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):